Protalix BioTherapeutics Files 2024 10-K
Ticker: PLX · Form: 10-K · Filed: Mar 17, 2025 · CIK: 1006281
| Field | Detail |
|---|---|
| Company | Protalix Biotherapeutics, Inc. (PLX) |
| Form Type | 10-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biotech, financials
TL;DR
Protalix BioTherapeutics filed its 2024 10-K, detailing financials for year-end Dec 31, 2024. Check for updates on their biotech pipeline.
AI Summary
Protalix BioTherapeutics, Inc. filed its 2024 10-K on March 17, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the biological products sector. Key financial data such as retained earnings and additional paid-in capital as of December 31, 2024, were reported.
Why It Matters
This filing provides investors with a comprehensive overview of Protalix BioTherapeutics' financial health and operational performance for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — Biotechnology companies often face inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-17 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Protalix BioTherapeutics, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-17 (date) — Filing date
- DE (state) — State of incorporation
- 201-696-9345 (phone_number) — Business phone number
FAQ
What is Protalix BioTherapeutics' primary business segment?
Protalix BioTherapeutics operates in the Biological Products (No Diagnostic Substances) sector, SIC code 2836.
When did Protalix BioTherapeutics change its name from ORTHODONTIX INC?
The company changed its name from ORTHODONTIX INC on April 22, 1998.
What is the SEC file number for Protalix BioTherapeutics?
The SEC file number for Protalix BioTherapeutics is 001-33357.
What is the business address of Protalix BioTherapeutics?
The business address is 2 University Plaza, Suite 100, Hackensack, NJ 07601.
What accounting standards updates are mentioned in relation to retained earnings and additional paid-in capital for 2023?
The filing mentions 'srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AccountingStandardsUpdate202006Member' in relation to retained earnings and additional paid-in capital for the period ending December 31, 2023.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 17, 2025 regarding Protalix BioTherapeutics, Inc. (PLX).